Archemix Corp. announced today the appointment of James Gilbert, M.D., as Chief Medical Officer and Senior Vice President of Clinical and Regulatory Affairs.
Dendritic Nanotechnologies Inc. (DNT) and the National Cancer Institute (NCI) have entered into a Small Business Innovation Research (SBIR) contract valued at $850,000. The project will use DNT's Priostar(TM) dendrimers to develop a new generation of targeted diagnostic and therapeutic delivery technology for the early detection and treatment of epithelial ovarian cancer. Annual U.S. expenditures
Dendritic Nanotechnologies Inc. and the National Cancer Institute have entered into a Small Business Innovation Research contract valued at $850,000. The project will use DNT's Priostar dendrimers to develop a new generation of targeted diagnostic and therapeutic delivery technology for the early detection and treatment of epithelial ovarian cancer.
Vancouver, BC, September 28, 2006--(T-Net)--Cardiome Pharma (NASDAQ: CRME / TSX: COM) today announced that RSD1235 has been assigned the name vernakalant hydrochloride by the United States Adopted Names (USAN) Council.
ROCKVILLE, Md.----Second graph, first sentence of the release should read: RX-10100 is a unique chemical compound that, based on preclinical studies, supports the treatment of anxiety, depression, and other behavioral diseases.
Cardiome Pharma Corp. today announced that RSD1235 has been assigned the name vernakalant hydrochloride by the United States Adopted Names Council. All future references to RSD1235 will now be vernakalant , and references to RSD1235 will be vernakalant .
ROCKVILLE, Md.----Rexahn , a clinical stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer and disorders of the central nervous system , announced today that a European patent has been granted for the treatment of behavioral diseases with its leading CNS drug candidate, RX-10100.
CAMBRIDGE, Mass. & FREMONT, Calif.----Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that it has granted Quark Biotech, Inc. InterfeRx licenses to discover, develop, and commercialize RNAi therapeutics targeting the p53 and RTP801 genes for certain diseases.
LEXINGTON, Mass.----Indevus Pharmaceuticals, Inc. today announced that following an End of Phase II meeting with the FDA, the Company has established a clinical plan towards regulatory approval of pagoclone for the treatment of persistent developmental stuttering and will initiate a Phase III trial in the first half of 2007.
ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that it has completed patient enrollment in a Phase IIb clinical trial. The trial is designed to compare the safety and efficacy of 5-fluorouracil (5-FU) plus CoFactor(R) to 5-FU plus leucovorin in first line treatment of metastatic colorectal cancer. [click link for full article]